Pharmaceuticals News and Research

RSS

Successful reduction in the levels of aggregated Abeta with GSMs

EnVivo Pharmaceuticals today reported the successful reduction in the levels of aggregated Abeta or Beta-Amyloid in an aged transgenic model (Tg2576) of Alzheimer's disease with its lead gamma-secretase modulator (GSM) EVP-0962. The aggregated Abeta, containing predominately oligomeric and larger Abeta fibrillar species, is considered to be the toxic entity in Alzheimer's disease.

9 Dec 2009

Antithrombotic medication may increase risk of bleeding in dialysis patients undergoing PCI procedure

Approximately 20 percent of dialysis patients undergoing a percutaneous coronary intervention (PCI; procedure such as angioplasty) are given an antithrombotic medication they should not receive, which may increase their risk for in-hospital bleeding, according to a study in the December 9 issue of JAMA.

9 Dec 2009

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Transgenomic, Inc. announced today the launch of its SURVEYOR Scan K-RAS kit, the first in a family of mutation detection kits the company plans to offer featuring its proprietary SURVEYOR Nuclease and WAVE® HS DHPLC platform. SURVEYOR Scan technology is a novel approach to mutation detection that uses a PCR amplification reaction and hybridization to form heteroduplex DNA molecules in samples with K-RAS mutation.

9 Dec 2009

Mylan Pharmaceuticals signs settlement and license agreements with Wyeth

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into settlement and license agreements with Wyeth, now part of Pfizer, relating to Venlafaxine Hydrochloride (HCl) Extended Release (ER) Capsules, 37.5 mg, 75 mg and 150 mg, the generic version of Wyeth's Effexor XR® Capsules, a treatment for major depressive disorder.

9 Dec 2009

FDA cleared, non-invasive prescription therapeutic device for NVP now available

PrimaBella™, the only non-invasive prescription therapeutic device cleared by the U.S. Food and Drug Administration (FDA) for the treatment of nausea and vomiting due to pregnancy (NVP), is now available. Providing a non-invasive, drug-free treatment for morning sickness, PrimaBella™ has been proven to be safe for both mother and developing baby and can offer quick relief -- the majority of patients report an immediate improvement in NVP symptoms.

9 Dec 2009

Epizyme closes Series B financing to a total of $40 million

Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M.

9 Dec 2009

Scientists identify new potential drug for treating acute myeloid leukaemia

EUREKA project E! 3172 NKSTIM has produced a new potential drug to stimulate cancer patients' own 'natural killer' cells to attack and eliminate cancer cells; currently undergoing clinical testing in patients with leukaemia or myeloma.

8 Dec 2009

House Democrats criticize recent increases in brand-name drug prices

The Wall Street Journal: "Reports of prescription drug-price increases have congressional Democrats complaining about price gouging and questioning whether drug companies are reneging on a pledge to provide billions of savings as part of a U.S. health-care overhaul sought by President Barack Obama.

8 Dec 2009

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company’s oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.

8 Dec 2009

CSL Behring selects BioRx as an approved Berinert provider

BioRx, a specialty pharmacy company, has been named one of a small number of approved providers of Berinert®. Berinert® is a plasma-derived concentrate of C1 esterase inhibitor (human) indicated for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients. CSL Behring, the manufacturer of Berinert® selected BioRx as part of their distribution network to launch this exciting new product in the United States.

8 Dec 2009

Micromet presents final data from its blinatumomab Phase 2 study for ALL

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL).

8 Dec 2009

Drug reimportation emerges again in health debate

The Hill reports that Senate Majority Leader Harry Reid "has agreed to allow Sen. Byron Dorgan (D-N.D.) to bring an amendment to a vote this week that would allow the importation of cheaper prescription drugs from abroad despite the fact that it could blow up a truce between the White House, Senate Finance Committee Chairman Max Baucus (D-Mont.) and the Pharmaceutical Research and Manufacturers of America (PhRMA) on healthcare reform." Sen. Olympia Snowe (R-Maine) is among the amendment's co-sponsors.

8 Dec 2009

Rib-X Pharmaceuticals, Yale University expand agreement to explore new ribosome technology

Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of serious multi-drug-resistant infections, announced today it has entered into a further license agreement with Yale University in the area of ribosome and antibiotic structure and function.

8 Dec 2009

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, presented data demonstrating that ACE-536 promotes formation of red blood cells through inhibition of members of the TGF-beta superfamily, at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Hemaquest Pharmaceuticals' HQK-1001 holds promise for sickle cell disease and beta thalassemia

HemaQuest Pharmaceuticals presented data from new preclinical studies and early results from clinical trials of its lead drug candidate, HQK-1001, in sickle cell disease and beta thalassemia at the annual meeting of the American Society of Hematology in New Orleans.

8 Dec 2009

Brazil: The largest emerging pharmaceutical market for hepatitis C virus

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that at approximately $120 million, the hepatitis C virus drug market in Brazil is among the largest emerging pharmaceutical markets for the disease.

8 Dec 2009

Three university academic groups sponsored for the MetaMiner project

GeneGo, Inc., the leading systems biology tools company, announced today that Millipore Corporation has sponsored academic groups from University of Queensland, Sheffield and USC to become members of the collaborative MetaMiner (Stem Cells) project run by GeneGo. MetaMiner is a partnership program for the reconstruction of stem cell pathways and their application in analysis of experimental data as well as knowledge mining.

8 Dec 2009

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.

8 Dec 2009

New data provide comprehensive review of emerging role of small airways in asthma management

Teva Respiratory, a division of Teva Pharmaceutical Industries Ltd., today announced the publication of four articles in a special supplement of the December issue of the Journal of Allergy and Clinical Immunology (JACI), providing a comprehensive scientific review of the emerging role of the small airways in the understanding and treatment of asthma.

8 Dec 2009

$Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma$

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib.

8 Dec 2009

Pharmaceuticals News and Research

Successful reduction in the levels of aggregated Abeta with GSMs

Antithrombotic medication may increase risk of bleeding in dialysis patients undergoing PCI procedure

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Mylan Pharmaceuticals signs settlement and license agreements with Wyeth

FDA cleared, non-invasive prescription therapeutic device for NVP now available

Epizyme closes Series B financing to a total of $40 million

Scientists identify new potential drug for treating acute myeloid leukaemia

House Democrats criticize recent increases in brand-name drug prices

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

CSL Behring selects BioRx as an approved Berinert provider

Micromet presents final data from its blinatumomab Phase 2 study for ALL

Drug reimportation emerges again in health debate

Rib-X Pharmaceuticals, Yale University expand agreement to explore new ribosome technology

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

Hemaquest Pharmaceuticals' HQK-1001 holds promise for sickle cell disease and beta thalassemia

Brazil: The largest emerging pharmaceutical market for hepatitis C virus

Three university academic groups sponsored for the MetaMiner project

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

New data provide comprehensive review of emerging role of small airways in asthma management

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence